We are releasing our unique off-target analysis service today. This novel service, enables de-risking drug development at an early stage utilizing the information about the composition of proteins in the human body, viruses, or diseases and extracts knowledge on how these proteins interact with drugs and other small molecules. Using artificial intelligence based algorithms, we can now search among hundreds of thousands of proteins and drugs for suitable associations to search and find unwanted protein targets that lead to side effects.
Read more: https://www.biorxiv.org/content/10.1101/2020.07.24.219071v1